Skip to main content

Table 4 Predictors for upgrade to ductal carcinoma in situ (DCIS) with invasive component (IC) in pre-operative biopsy diagnosed DCIS patients

From: Revisit the practice of lymph node biopsy in patients diagnosed as ductal carcinoma in situ before operation: a retrospective analysis of 682 cases and evaluation of the role of breast MRI

N = 682 Post-OP pure DCIS (N = 449) Post-OP upgrade to DCIS-IC (N = 233) P value
Age, year 52 ± 9.8 52.9 ± 10.8 0.29
Location    0.62
Right 219(48.8) 109(46.8)  
Left 230(51.2) 124(53.2)  
Biopsy method N/A = 2 N/A = 1  < 0.01
CNB 233(52.1) 188(81)  
Stereotactic biopsy 140(31.3) 27(11.6)  
Excisional biopsy 71(15.9) 17(7.3)  
MMG 3(0.7) 0(0)  
Sonogram tumor size, cm 1.9 ± 1.1 2.2 ± 1.2  < 0.01
Mammogram tumor size, cm 2.4 ± 1.3 2.8 ± 1.1 0.14
MRI tumor size, cm 3.6 ± 2.2 4.5 ± 2.1  < 0.01
Pathology tumor sizea, cm 2.7 ± 2.7 1.4 ± 1.9  < 0.01
Gross tumor sizeb, cm 3.3 ± 2.4 3.8 ± 2.4 0.02
Stage (N/A = 33) N/A = 31 N/A = 2  < 0.01
0 381(91.1) 9(3.9)  
I 26(6.2) 157(68.0)  
II 10(2.4) 55(23.8)  
III 1(0.2) 10(4.3)  
Grade (N/A = 74) N/A = 44 N/A = 30  < 0.01
I 28(6.9) 48(23.6)  
II 211(52.1) 126(62.1)  
III 166(41.0) 29(14.3)  
ER N/A = 24    < 0.01
Positive 335(78.8) 149(63.9)  
Negative 90(21.2) 84(36.1)  
PR (N/A = 33) N/A = 33    < 0.01
Positive 303(72.8) 135(57.9)  
Negative 113(27.2) 98(42.1)  
HER-2 (N/A = 203) N/A = 199 N/A = 4 0.25
Positive 99(39.6) 79(34.5)  
Negative 151(60.4) 150(65.5)  
MRI LN metastasis N/A = 184 N/A = 91 0.01
Yes 50(18.9) 44(31.0)  
No 215(81.1) 98(69.0)  
Lymph node stage N/A = 61 N/A = 22  < 0.01
N0 385(99.2) 164(77.7)  
N1 2(0.5) 38(18.0)  
N2 0(0) 7(3.3)  
N3 1(0.3) 2(0.9)  
OP method     < 0.01
Total 255(56.8) 175(75.1)  
Partial 194(43.2) 58(24.9)  
LN meta N/A = 30 N/A = 3  < 0.01
Yes 3(0.7) 46(20.0)  
No 416(99.3) 184(80.0)  
Method_LN     < 0.01
SLNB 365(81.3) 163(70.0)  
SLNB + ALND 14(3.1) 35(15.0)  
ALND 18(4.0) 25(10.7)  
ND 52(11.6) 10(4.3)  
  1. MMG mammography-guided biopsy, LN lymph node, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, ND not done, OP operation, DCIS ductal carcinoma in situ, TNBC triple negative breast cancer, ER estrogen receptor, PR progesterone receptor, HER-2 human epithelial grow receptor type 2, N/A not available
  2. aPathology tumor size: in pure DCIS cases pathologic tumor size=DCIS tumor size, if containing invasive component then pathologic tumor size=invasive cancer tumor size,
  3. bGross tumor size: invasive + non-invasive component tumor size